• eTheRNA
  • Developing safe, convenient and effective mRNA immunotherapies for the patient

The pipeline

eTheRNA aims to provide preclinical and clinical proof of evidence to support the further development of the TriMix technology into an injectable in vivo product, that can be made available "off-the-shelf".

In parallel, eTheRNA will use non-dilutive funds and will seek partners to develop the TriMix ex vivo/cellular therapy as a personalized therapy for patients for whom cellular therapy could be an alternative treatment.


R&D pipeline